Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease.

Department of Clinical and Experimental Medicine, Federico II University Medical School of Naples, Italy.
Clinical and investigative medicine. Medecine clinique et experimentale (Impact Factor: 1.15). 01/2008; 31(1):E24-9.
Source: PubMed

ABSTRACT Non-Alcoholic Fatty Liver Disease occurs mainly in severly obese patients and its relationship to Metabolic Syndrome is increasingly recognized. The aim of this study was to determine energy production-utilization by measuring the Basal Metabolic Rate in severely obese patients, characterized by NAFLD, with or without Metabolic Syndrome. Then, the role of systemic inflammation was assessed.
Twenty severly obese men with Metabolic Syndrome were compared with a well-matched cohort of patients without Metabolic Syndrome. All showed hepatic steatosis at UltraSonography. Basal Metabolic Rate was measured by indirect calorimetry using a canopy system and single-frequency bio-impedance analysis. Serum Interleukin-6 and fibrinogen levels were measured as markers of inflammation
Basal Metabolic Rate was higher in severely obese patients with Metabolic Syndrome than in those without it: 2,496+/-358 kcal/d vs 2,126+/-253 kcal/d, P = 0 .001. Laboratory findings of concurrent chronic inflammation were also higher in these patients, i.e., Il6 4.35+/-1.34 pg/ml vs 6.23+/-2.1 pg/ml, P = 0.034; fibrinogenemia 285+/-40 mg/dL vs 376+/-91 mg/dL, P = 0.020; these of of cytonecrosis, i.e., AlaninaminoTransferase, equally behaved 32.3+/-7.9 UI vs 65.7+/-28.2 UI, P < 0.001. Visceral adiposity and arterial hypertension were more frequently detected in patients with Metabolic Syndrome.
Increased energy expenditure, observed in morbidly obese patients as a consequence of a systemic, low-grade, inflammatory process, may explain progression from obesity to Metabolic Syndrome, independent of the presence of NAFLD. In this context, increased Basal Metabolic Rate may be a clue of Metabolic Syndrome.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis is a chronic inflammatory process of the vessel walls, and CD4+ T-cells are peculiar to both human and murine atherosclerotic lesions. There is a recent line of research favoring hypothetic allergic mechanisms in the genesis of atherosclerosis and, consequently, coronary artery disease (CAD), among which Interleukin (IL)-17 appears to be a key cytokine regulating local tissue inflammation.The objective was to add a piece of information on the role of IL-17 in the genesis of atherosclerosis. Eighty obese patients with normal liver enzyme levels but presenting with ultrasonographic evidence of NAFLD formed the population of this cross-sectional study. Anthropometric measures, data on excess adiposity, metabolic profile, serum concentrations of IL-17, eotaxin-3, IL-8, and CCL4/MIP1ß, C-reactive protein, fibrinogen, ferritin, TNF-¿, as well carotid intima-media thickness (IMT), a marker of atherosclerosis, and the main risk factors for CAD, such as blood pressure and smoking status, but also less determinant ones such as degree of NAFLD severity, Intramuscular Triglyceride storage and Resting Metabolic Rate were evaluated.Serum concentrations of Il-17 were detected as related to those of inflammatory cytokines, IL-6, IFN-¿ and TNF-¿. Furthermore, circulating levels of IL-17 were linked to those mirroring allergic process, IL-8, CCL4/MIP1ß and eotaxin. Early atherosclerosis, evidenced as increased IMT, was not associated with circulating IL-17 levels. At multiple regression, IMT was predicted, other than by age, by the amount of the visceral adiposity, expressed as visceral adipose tissue at ultrasonography, and by serum eotaxin.In conclusion, a strong relationship was found between the IL-17-related chemokine eotaxin and IMT. The association found between the amount of visceral fat and circulating levels of eotaxin on the one hand, and IMT on the other, could reinforce the hypothesis that IL-17, released by the visceral adipose tissue, induces eotaxin secretion via the smooth muscle cells present in the atheromatosus vessels.
    Journal of Translational Medicine 08/2014; 12(1):214. DOI:10.1186/s12967-014-0214-1 · 3.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Metabolic Syndrome (MS) is associated with a systemic inflammatory response that plays an important pathogenetic role in atherothrombotic disease. Highly sensitive C-reactive protein (hsCRP) and fibrinogen are acute phase reactants and indicate underlying inflammatory state. We studied inflammatory markers in 50 Indian subjects with MS diagnosed by IDF criteria and 24 healthy age and sex matched controls. Clinical evaluation included anthropometry, body fat analysis by bio-impedance, biochemical, hsCRP, fibrinogen and insulin measurement. Subjects with MS had higher hsCRP (4.07 ± 1.72 vs. 2.09 ± 0.98 mg/L, P = 0.0006); and fibrinogen levels (336 ± 77 vs. 193 ± 43 mg/dl, P
    International Journal of Diabetes in Developing Countries 09/2012; 32(3):131-137. DOI:10.1007/s13410-012-0080-4 · 0.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stress places a metabolic burden on homeostasis and is linked to heightened sympathetic activity, increased energy expenditure and pathology. The yogic state is a hypometabolic state that corresponds with mind-body coherence and reduced stress. This study aimed to investigate metabolic responses to stress and different yoga practices in regular yoga practitioners (YP), non-yoga practitioners (NY) and metabolic syndrome patients (MS).
    BMC Complementary and Alternative Medicine 11/2014; 14(1):445. DOI:10.1186/1472-6882-14-445 · 1.88 Impact Factor

Full-text (2 Sources)

Available from
Jun 2, 2014